Randomized trial · people
Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, semaglutide's effect on how much people ate came with less hunger and fewer cravings, while there was no sign of slowed stomach emptying after 20 weeks.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 72
- Published
- 2021
- Journal
- Diabetes Obes Metab
What they tested
The team wanted to know how weekly semaglutide 2.4 mg shots change stomach emptying, appetite and how much people eat in adults with obesity.
How the study was done
A randomized, double-blind, placebo-controlled trial in 72 adults with obesity, who got weekly semaglutide under the skin (raised step by step to 2.4 mg) or placebo, a dummy shot, for 20 weeks. Stomach emptying was checked by how fast paracetamol was absorbed after a set breakfast, and food intake was measured at a lunch where people could eat as much as they wanted.

Model. Individual results vary.
What they found
At week 20, people on semaglutide ate 35% less energy at the eat-as-much-as-you-like lunch than those on placebo (1736 versus 2676 kJ; a difference of -940 kJ). They also reported less hunger and fewer thoughts about how much they would eat, felt fuller and more satisfied, and on the Control of Eating Questionnaire scored better control of eating with fewer and weaker food cravings. Paracetamol uptake over 5 hours was 8% higher with semaglutide, but this was no longer significant once body weight was taken into account, and other paracetamol measures did not change, so the researchers found no evidence that stomach emptying was slowed at week 20. Body weight fell by 9.9% with semaglutide and 0.4% with placebo.
What it doesn’t show
The trial ran for 20 weeks in adults with obesity, so it doesn't show what happens over longer use or in other groups. Stomach emptying was judged indirectly from paracetamol absorption, and food intake came from a test lunch rather than everyday eating.
The paper
Friedrichsen et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.